Pushing the limits: defeating leukemia stem cells by depleting telomerase.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25479742.
- Also identified by DOI 10.1016/j.stem.2014.11.014 and PMC identifier 4394378.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Leukemia stem cells (LSCs), featuring unlimited self-renewal capacity and chemoresistance, are critical cellular targets for new treatments to improve outcomes for acute myeloid leukemia (AML). In this issue of Cell Stem Cell, Bruedigam et al. (2014) demonstrate that inhibition of telomerase is damaging to LSCs and may represent a promising therapeutic approach in AML.
Medical subject headings
- Indoles
- Leukemia, Myeloid, Acute
- Neoplastic Stem Cells
- Niacinamide
- Telomerase
- Tumor Suppressor Protein p53